Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

SERRETTA, Vincenzo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 20.380
EU - Europa 11.919
AS - Asia 9.093
SA - Sud America 1.423
Continente sconosciuto - Info sul continente non disponibili 847
AF - Africa 254
OC - Oceania 35
Totale 43.951
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 19.929
RU - Federazione Russa 3.366
SG - Singapore 3.186
CN - Cina 2.286
IT - Italia 2.204
FI - Finlandia 1.150
BR - Brasile 1.093
DE - Germania 1.051
UA - Ucraina 1.013
HK - Hong Kong 904
VN - Vietnam 840
IE - Irlanda 596
PL - Polonia 585
GB - Regno Unito 553
FR - Francia 468
BD - Bangladesh 415
SE - Svezia 382
JP - Giappone 363
KR - Corea 225
IN - India 220
CA - Canada 218
BE - Belgio 103
AR - Argentina 98
RO - Romania 98
IQ - Iraq 94
MX - Messico 87
NL - Olanda 79
CI - Costa d'Avorio 69
TR - Turchia 66
CO - Colombia 60
AT - Austria 59
VE - Venezuela 55
PK - Pakistan 53
ZA - Sudafrica 53
ES - Italia 49
ID - Indonesia 49
EC - Ecuador 44
UZ - Uzbekistan 43
MY - Malesia 39
CH - Svizzera 37
PH - Filippine 34
AE - Emirati Arabi Uniti 32
CZ - Repubblica Ceca 31
AU - Australia 30
CL - Cile 29
JM - Giamaica 29
SA - Arabia Saudita 29
CR - Costa Rica 26
EG - Egitto 25
MA - Marocco 25
JO - Giordania 21
IL - Israele 18
IR - Iran 18
AZ - Azerbaigian 17
HN - Honduras 17
KZ - Kazakistan 17
TN - Tunisia 16
AL - Albania 14
DZ - Algeria 14
KE - Kenya 14
LB - Libano 14
NP - Nepal 14
GR - Grecia 13
PY - Paraguay 13
TH - Thailandia 13
BH - Bahrain 12
LT - Lituania 12
UY - Uruguay 12
GE - Georgia 11
BB - Barbados 10
GT - Guatemala 10
RS - Serbia 10
TW - Taiwan 10
OM - Oman 9
PE - Perù 9
TT - Trinidad e Tobago 9
BG - Bulgaria 8
BO - Bolivia 8
DO - Repubblica Dominicana 8
NI - Nicaragua 8
PS - Palestinian Territory 8
AO - Angola 7
NG - Nigeria 7
PA - Panama 7
PT - Portogallo 7
EU - Europa 6
KW - Kuwait 6
MD - Moldavia 6
SV - El Salvador 6
AM - Armenia 5
NZ - Nuova Zelanda 5
PR - Porto Rico 5
BA - Bosnia-Erzegovina 4
DK - Danimarca 4
ET - Etiopia 4
LY - Libia 4
SY - Repubblica araba siriana 4
XK - ???statistics.table.value.countryCode.XK??? 4
BN - Brunei Darussalam 3
BY - Bielorussia 3
Totale 43.056
Salva come PNG Salva come JPEG
Città #
Ashburn 2.569
Singapore 2.059
Fairfield 1.632
San Jose 1.543
Chandler 1.084
Woodbridge 868
Hong Kong 852
Wilmington 826
Ann Arbor 759
Houston 717
Seattle 643
Dublin 594
Jacksonville 536
Cambridge 515
Zgierz 511
Moscow 427
Medford 415
Beijing 401
Council Bluffs 401
New York 342
Tokyo 342
Los Angeles 324
Santa Clara 314
Des Moines 284
Ho Chi Minh City 275
Nanjing 275
Frankfurt am Main 267
Princeton 267
Dallas 258
Lauterbourg 221
Boardman 216
Hanoi 206
Palermo 193
Helsinki 182
Altamura 171
The Dalles 161
Hefei 157
Tulsa 150
Lawrence 137
Milan 137
Buffalo 134
Dearborn 122
Chicago 110
Nanchang 109
San Diego 109
São Paulo 102
Brussels 98
Shenyang 92
Orem 84
Rome 74
Hebei 73
Changsha 70
Abidjan 69
Tianjin 65
Columbus 64
Denver 62
Jiaxing 62
Montreal 62
Brooklyn 61
London 61
Ludwigshafen am Rhein 61
Nuremberg 61
Phoenix 58
Toronto 55
Munich 52
Da Nang 51
Guangzhou 47
San Francisco 46
Seongnam 46
Warsaw 46
Jinan 45
Chennai 43
Kumar 43
Saint Petersburg 43
Amsterdam 42
Atlanta 40
Verona 40
Zhengzhou 38
Haiphong 37
Redwood City 37
Venice 36
Baghdad 34
Bremen 34
City of London 34
Tashkent 34
Nave 33
Boston 32
Rio de Janeiro 32
Auburn Hills 30
Belo Horizonte 30
Seoul 30
Johannesburg 29
Washington 27
Falls Church 26
Manchester 26
Ningbo 26
San Mateo 26
Paris 25
San Paolo di Civitate 25
Dhaka 24
Totale 25.438
Salva come PNG Salva come JPEG
Nome #
S9-Fibronectin, EGF-R, HB-EGF:biomarkers of urothelial damage during intravesical adjuvant therapy? 618
PROSPECTIVE, RANDOMIZED, CROSSOVER COMPARISON OF SUBLINGUAL APOMORPHINE (3 mg) WITH ORAL SILDENAFIL (50 mg) FOR MALE ERECTILE DYSFUNCTION 539
Correlation between chronic prostatitis syndrome and pelvic venous disease. A survey of 2554 urologic outpatients 392
Clinical and biochemical markers of visceral adipose tissue activity: Body mass index, visceral adiposity index, leptin, adiponectin, and matrix metalloproteinase-3. Correlation with Gleason patterns 4 and 5 at prostate biopsy 352
Characterization of human infiltrating and circulating gamma-delta t cells in prostate cancer 313
Manuale di Urologia e Andrologia. Capitolo 1: Anatomia dell'apparato genito-urinario 297
Drinking water source and cigarette smoking in transitional cell carcinoma of the bladder. 295
Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer Patients Progressing after Docetaxel: A Prospective Single-Center Study 291
A phase I-II study on intravesical Gemcitabine in superficial bladder papillary tumors 287
Prospective, randomized, crossover comparison of sublingual apomorphine (3 mg) with oral sildenafil (50 mg) for male erectile dysfunction. 286
A 1-year maintenance after early adjuvant intravesical chemotherapy has a limited efficacy in preventing recurrence of intermediate risk non-muscle-invasive bladder cancer. 284
Can we clinically distinguish anejaculation from retrograde ejaculation in patients on α1A-blockers therapy for lower urinary tract symptoms? 276
Whatsapp messenger as a tool for the multidisciplinary management in everyday clinical practice 273
Correlation between GP-170 expression, prognosis, and chemoresistance of superficial bladder carcinoma 269
Cytokine gene expression in the tunica albuginea 
of patients with Peyronie’s disease. Pilot study with 
a control group 251
Segmental resection of distal ureter with termino-terminal ureteric anastomosis vs bladder cuff removal and ureteric re-implantation for upper tract urothelial carcinoma: results of a multicentre study 246
PSA reduction (after antibiotics) permits to avoid or postpone prostate biopsy in selected patients 242
Modificazioni del PSA dopo terapia antibiotica in pazienti candidati alla biopsia prostatica. 241
WHATSAPP MESSENGER AS A REAL-TIME TOOL FOR A LONG-DISTANCE ACTIVITY OF A MULTIDISCIPLINARY 237
Cytokines gene expression in the tunica albuginea of patients with Peyronie’s disease. Pilot study with a control group 235
Clinical implications of a rare renal entity: Pleomorphic Hyalinizing Angiectatic Tumor (PHAT) 230
Il carcinoma prostatico in Calabria e Sicilia. 229
A randomized trial comparing tamoxifen therapy vs. tamoxifen prophylaxis in bicalutamide-induced gynecomastia. 226
Hypofractionated postoperative helical tomotherapy in prostate cancer: a mono-institutional report of toxicity and clinical outcomes 225
Intravesical chemotherapy for intermediate risk non-muscle invasive bladder cancer recurring after a first cycle of intravesical adjuvant therapy 223
Recurrence and progression according to stage at re-TUR in t1g3 bladder cancer patients treated with BCG: Not as bad as previously thought 220
Preliminary report of a multicentric study on environmental risk factors in Ta-T1 transitional cell carcinoma of the bladder 219
Cytokines gene expression in the tunica albuginea in patients with Peyronie’s disease. Pilot study with a control group 219
Analisi preliminare dei fattori demografici ed eziopatogenetici in pazienti affetti da carcinoma vescicale a medio rischio di recidiva 217
Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder 217
Valore clinico della riduzione del PSA in soggetti candidati all’agobiopsia prostatica 216
Management of bicalutamide induced gynaecomastia. A randomized study comparing therapy versus prophylaxis with tamoxifen. 216
POSITIVITA’ DELL’NMP22 E NEGATIVITA’ CISTOSCOPICA E CITOLOGICA. QUALE SIGNIFICATO ATTRIBUIRE? 215
Does the Compliance to Intravesical BCG Differ between Common Clinical Practice and International Multicentric Trials? 215
Fumo, risorsa idrica ed altri fattori di rischio nel carcinoma vescicale superficiale 213
Mitomycin C from birth to adulthood 213
La terapia dei tumori vescicali superficiali: lo stato attuale 210
Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of the bladder: Phase I-II study on marker lesions 210
Sarcomatoid carcinoma of urinary bladder: Immunohistochemical study of an uncommon case 210
TERAPIA CONSERVATIVA DELL'UROTELIOMA VESCICALE T1G3. RISULTATI SU 235 PAZIENTI 209
How Can the COVID-19 Pandemic Lead to Positive Changes in Urology Residency? 208
The activity of intravesical hyaluronic acid and chondroitin sulfate administration on urothelial gene expression. Preliminary results on the epidermal growth factor receptor and fibronectin gene expression evaluated in bladder washings of patients affected by non muscle-invasive bladder cancer 208
Carcinoma uroteliale in cisti pielogena 206
Sildenafil orodispersible film in the treatment of erectile dysfunction after radical prostatectomy: A single-centre open-label uncontrolled trial 206
Distribution of smoking, water resource and other environmental factors in patients affected by superficial bladder cancer 205
Genitourinary Symptoms-Patient Help-Seeking and General Practitioner Management: An Outpatient Based Survey at a Tertiary Hospital in Southern Italy 205
Intravesical gemcitabine in superficial bladder tumours preliminary results of a phase I-II study 203
IS VISCERAL ADIPOSITY INDEX (VAI)RELATED TO PROSTATE CANCER DETECTED BY BIOPSY? 202
La p53 nel tumore vescicale superficiale (Ta-T1, G1-3) 200
Correlation between BMI and the pathological features of prostate cancer at biopsy 200
Chemioterapia adiuvante e fattori di rischio ambientale nel carcinoma vescicale superficiale a medio rischio di recidiva. Uno studio prospettico randomizzato del Gruppo Studio Tumori Urologici (GSTU). 198
Chemioterapia adiuvante e fattori di rischio ambientale nel carcinoma vescicale superficiale a medio rischio di recidiva. Uno studio prospettico randomizzato del Gruppo Studi Tumori Urologici (GSTU) 198
Multiplicity and history have a detrimental effect on survival in patients with T1G3 bladder tumors selected for conservative treatment. 197
Re: Urinary pH is Highly Associated With Tumor Recurrence During Intravesical Mitomycin C Therapy for Nonmuscle Invasive Bladder Tumor 196
INTRAVESICAL GEMCITABINE IN SUPERFICIAL BLADDER TUMOURS.RESULTS OF A PHASE I-II STUDY 195
BIOMARKERS OF UROTHELIAL DAMAGE IN PATIENTS TREATED BY ADJUVANT INTRAVESICAL THERAPY 195
PROSTATA (PROSTATITI, IPERTROFIA PROSTATICA, CANCRO DELLA PROSTATA) 194
Fibronectin (FN), epidermal growth factor-receptor (EGF-R) and heparin-binding epidermal growth factor-like (HB-EGF) urinary expressions and topical toxicity of adjuvant intravesical therapy for non muscle invasive bladder cancer (NMI-BC) 194
Epidermal Growth Factor Receptor (EGFR) Cell Expression During Adjuvant Treatment After Transurethral Resection for Non-Muscle-Invasive Bladder Cancer: A New Potential Tool to Identify Patients at Higher Risk of Disease Progression 194
Ruolo prognostico della p53 nel tumore vescicale superficiale. Correlazione con recidiva e progressione – 193
Fumo di sigaretta e risorsa idrica in pazienti affetti da carcinoma vescicale superficiale. XV Congresso Nazionale SIUro, Giardini Naxos 3-6 novembre 2005. 1. 192
Attività lavorativa e fattori di rischio ambientale in pazienti affetti da carcinoma vescicale superficiale. 192
T1HG Bladder Tumours: So Many Papers, Do We Need Them? Yes, We Do! 192
Plasma levels of angiogenetic markers in men candidate to prostate biopsy 192
Compliance to therapy with Dapoxetine in comparison to a conventional selective serotonin reuptake inhibitor (Citalopram) in 118 patients with premature ejaculation. 192
Modificazioni del PSA dopo terapia antibiotica in pazienti candidati alla biopsia prostatica 190
Does Exist A Correlation Between BMI and Gleason Patterns 4 and 5 At Prostate Biopsy? 190
Segmental ureterectomy vs. radical nephroureterectomy for ureteral carcinoma in patients with a preoperative glomerular filtration rate less than 90 ml/min/1.73 m2: A multicenter study 190
Fattori di rischio ambientali nella storia naturale del carcinoma vescicale superficiale. 189
The clinical value of PSA increase during intravesical adjuvant therapy for nonmuscle-invasive bladder cancer. 189
High-Grade T1 on Re-Transurethral Resection after Initial High-Grade T1 Confers Worse Oncological Outcomes: Results of a Multi-Institutional Study 189
Studio randomizzato sul ruolo del mantenimento nella chemioprofilassi endovescicale precoce dopo TUR con Epirubicina. XVI Congresso Nazionale Società Italiana di Urologia Oncologica. 30 Novembre - 3 Dicembre 2006. Arch. Ital. Urol. Androl. vol. , pp. 71. ISBN/ISSN: 1124-3562. 188
Studio pilota sul valore predittivo dei livelli plasmatici di 9 fattori angiogenetici nella selezione di pazienti candidati alla biopsia prostatica 188
CHEMIOPROFILASSI PRECOCE CON EPIRUBICINA AD ALTA DOSE NEL CARCINOMA VESCICALE SUPERFICIALE. STUDIO RANDOMIZZATO DEL GSTU 187
The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer 187
An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer 187
TUR AND ADJUVANT INTRAVESCICAL CHEMOTHERAPY IN T1G3 BLADDER TUMORS. RECURRENCE, PROGRESSION AND SURVIVAL IN 137 SELECTED PATIENTS FOLLOWED UP TO 20 YEARS. 185
Water Chlorination and other environmental factors in bladder cancer. Result of a multicentre study. 184
Survival risk factors in T1G3 non-muscle-invasive (NMI) bladder cancer consevatively treated. Long term results. 182
A case of renal carcinoma metastasis simulating a thyroid goiter 182
Validation of Neutrophil-to-lymphocyte Ratio in a Multi-institutional Cohort of Patients With T1G3 Non-muscle-invasive Bladder Cancer 182
Acute and late toxicity and preliminary outcomes report of moderately hypofractionated helical tomotherapy for localized prostate cancer: a mono-institutional analysis 182
Intravesical gemcitabine is superficial bladder tumours. Results of a phase I-II study 181
Fattori di rischio ambientale nel carcinoma vescicale superficiale. Risultati su 577 pazienti sottoposti a chemioterapia endovescicale adiuvante 181
ESTRAMUSTINA FOSFATO VS ASSOCIAZIONE A BASSA DOSE DI ESTRAMUSTINA FOSFATO E ETOPOSIDE NEL CARCINOMA PROSTATICO ORMONOREFRATTARIO (HRPC). STUDIO RANDOMIZZATO DI FASE II DEL GRUPPO STUDI TUMORI UROLOGICI (GSTU) 180
Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer 180
Are referral centers for non-muscle-invasive bladder cancer compliant to EAU guidelines? A report from the vesical antiblastic therapy Italian study 180
Cigarette Smoking Status at Diagnosis and Recurrence in Intermediate-risk Nonemuscle-invasive Bladder Carcinoma 180
Efficacia del mantenimento nella chemioprofilassi endovescicale precode dopo TUR. Risultati di uno studio randomizzato multicentrico. 179
Fattori di rischio ambientale nel carcinoma vescicale superficiale. Risultati su 577 pazienti sottoposti a chemioterapia endovescicale adiuvante. 179
Cigarette smoking and drinking water source: Correlation with clinical features and pathology of superficial bladder carcinoma. 179
Although rare, severe complications following intravesical bacillus Calmette-Guerin treatment should not be overlooked! 179
PLEOMORPHIC HYALINIZING ANGIOECTATIC TUMOR (PHAT) OF RENAL PARENCHYMA. FIRST CASE REPORTED IN LITERATURE 179
Ipertermia e chemioterapia nel tumore vescicale superficiale a medio-alto rischio:esperienza preliminare sulla tollerabilità. 178
A RANDOMIZED STUDY EVALUATING MAINTENANCE SCHEDULE IN EARLY ADJUVANT CHEMOTHERAPY FOR INTERMEDIATE RISK NON-MUSCLE-INVASIVE BLADDER CANCER. 178
PATIENT’S COMPLIANCE TO BCG. DO WE ADEQUATELY CONSIDER IT? 178
Significato clinico della positività della NMP22 in pazienti in follow-up per carcinoma vescicale superficiale. Risultati a lungo termine 177
Impact of stage migration on bladder cancer: A slow but steady improvement in the long term survival rates after radical cystectomy in the last 25 years 177
PSA and second-line therapy of hormone refractory prostate carcinoma 177
Chemioterapia domiciliare nel carcinoma prostatico ormonorefrattario (HRPC). Studio di fase II del gruppo studio tumori urologici (GSTU). 176
Totale 21.922
Salva come PNG Salva come JPEG
Categoria #
all - tutte 142.918
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 142.918
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.987 0 0 61 140 150 115 73 142 332 331 108 535
2022/20233.769 418 549 89 334 406 498 226 238 800 21 137 53
2023/20241.735 71 237 170 180 151 357 153 124 11 21 75 185
2024/20254.105 138 212 194 370 202 153 258 294 359 430 616 879
2025/202615.804 1.105 464 788 1.017 1.319 2.389 2.290 1.629 1.136 2.150 815 702
2026/20272.729 1.300 651 778 0 0 0 0 0 0 0 0 0
Totale 43.951